21 Best Biotech Stocks To Buy in 2025

Why Biotech Offers Explosive Growth Potential in 2025

Biotech stocks present investors with promising growth opportunities because the industry advances through innovative concepts and vital medical breakthroughs.

In 2025, the sector offers explosive growth potential as breakthroughs in gene editing, personalized medicine, and mRNA technology transition from research to commercial reality.

Although the industry faced a temporary slowdown in recent years, this has created attractive entry points for investors. Many biotech firms are now trading at discounted valuations while continuing to advance late-stage clinical pipelines and form strategic partnerships.

Investing now allows investors to capture the upside from new product launches, technological advances, and expanding market adoption throughout 2025 and beyond.

Understanding Biotech Investment Risks & Rewards

Biotech investing offers high return potential but also carries significant risk due to reliance on research outcomes, regulatory approvals, and funding stability.

Profits come when companies successfully develop and gain approval for new therapies, often driving strong revenue growth and stock surges. Yet, high R&D costs, long development timelines, and trial failures can quickly erode value.

Smart investors assess each firm’s financial strength, cash reserves, and pipeline progress. Balancing innovation potential with solid fundamentals helps navigate the biotech sector’s volatility while maximizing long-term rewards.

Top Biotech Stocks to Watch In 2025

Here is a list of 21 top biotech stocks to consider for your investment portfolio in October 2025:

1. Vertex Pharmaceuticals (VRTX)

2. Regeneron Pharmaceuticals (REGN)

3. Gilead Sciences (GILD)

4. Biogen (BIIB)

5. Alnylam Pharmaceuticals (ALNY)

6. Argenx (ARGX)

7. BioMarin Pharmaceutical (BMRN)

8. Incyte Corporation (INCY)

9. CRISPR Therapeutics (CRSP)

10. Beam Therapeutics (BEAM)

11. Intellia Therapeutics (NTLA)

12. Moderna (MRNA)

13. Genmab A/S (GMAB)

14. CSL Limited (CSL)

15. Novo Nordisk (NVO)

16. Lonza Group (LZAGY)

17. Karuna Therapeutics (KRTX)

18. Madrigal Pharmaceuticals (MDGL)

19. Viking Therapeutics (VKTX)

20. Summit Therapeutics (SMMT)

21. Structure Therapeutics (GPCR)

Vertex Pharmaceuticals (VRTX)

Current Price (28 October 2025): $387.18

The U.S.-based biopharmaceutical company Vertex maintains its position as the leading cystic fibrosis (CF) treatment provider through its dominant market position which reaches approximately 90% of global sales.

The company maintains its position as a leading biotech innovator through its aggressive expansion into gene editing and pain management and rare disease therapy development beyond its CF treatment dominance.

Key Details:

• Market Cap: ~$120.6 billion

• P/E ratio: 24.9

• Revenue (TTM): $11.10 billion

• YoY Growth: 9%

Investor Appeal:

The company maintains stability through its cystic fibrosis franchise which generates dependable cash flow while pursuing innovative developments.

The company maintains a strong position for future growth through its gene editing and non-opioid pain therapy pipeline and its commitment to rare disease research.

Regeneron Pharmaceuticals (REGN)

Current Price (28 October 2025): $585.31

The company Regeneron is a major biopharmaceutical player, known for its biologic therapies in ophthalmology (EYLEA®) and immunology/oncology (e.g., Dupixent® via partner). It continues to invest in next-generation platforms and manufacturing scale-up.

Key Details:

• Market Cap: ~$61.3 billion USD (Oct 2025)

• Revenue (TTM): ~$14.21 billion USD

• Revenue YoY Growth: ~5% (TTM)

• P/E Ratio: Not readily applicable

Investor Appeal:

Regeneron’s strength lies in its established biologic franchises combined with pipeline innovation and manufacturing capacity expansion. For investors seeking a well-capitalised biotech/biologic platform with both current cash flows and future growth levers, Regeneron offers a compelling opportunity.

Gilead Sciences (GILD)

Current Price (28 October 2025): $120.47

The company Gilead is a global biopharma leader in HIV, liver disease, and oncology therapies, with a broad product base and scale. It continues to evolve strategy toward higher-growth areas while managing legacy assets.

Key Details:

• Market Cap: ~$150.1 billion USD (Oct 2025)

• Revenue (TTM): ~$28.86 billion USD

• Revenue YoY Growth: ~3.8% for TTM ending June 2025

• P/E Ratio: Not clearly stated in the sources available

Investor Appeal:

Gilead offers scale, strong cash generation, and presence in large, stable disease markets (HIV/hepatology). For investors looking for a blue-chip biotech/biopharma with both defensive and moderate growth characteristics, Gilead is an attractive candidate.

Biogen (BIIB)

Current Price (28 October 2025): $150.43

The company Biogen is focused on neurology, with key assets in multiple sclerosis (MS) and Alzheimer’s disease, and is undergoing portfolio transformation toward rare diseases and immunology.

Key Details:

• Market Cap: ~$21.98 billion USD (Oct 2025)

• Revenue (TTM): ~$9.99 billion USD

• Revenue YoY Growth: ~3.4% up for last twelve months

Investor Appeal:

Biogen offers a transformation story: legacy neurology assets transitioning into rare disease and immunology, combined with cost discipline. This makes it of interest to investors with higher risk tolerance who are seeking possible turnaround upside.

Alnylam Pharmaceuticals, Inc. (ALNY)

Current Price (28 October 2025): $451.20

The company Alnylam leads the field of RNA interference (RNAi) therapeutics by providing first-in-class treatments for rare genetic diseases. The platform of the company continues to expand the possibilities of gene silencing technologies.

Key Details:

• Market Cap: $43.1 billion

• P/E ratio: Not applicable

• Revenue (TTM): $2.35 billion

• YoY Growth: 17.2%

Investor Appeal:

Alnylam stands as the worldwide leader in RNAi technology with strong intellectual property rights and established commercial success and promising future prospects in CNS and cardio-renal therapeutic areas. The company stands out as a long-term investment opportunity because of its high innovation level and recurring revenue stream.

Argenx (ARGX)

Current Price (28 October 2025): $829.83

Argenx develops antibody-based treatments for autoimmune diseases through its proprietary FcRn platform. Its lead product, VYVGART®, continues to expand globally across multiple indications.

Key Details:

• Market Cap: $49.6 billion

• P/E ratio: Not applicable

• Revenue (TTM): $3.12 billion

• YoY Growth: 88%

Investor Appeal:

Argenx shows exceptional revenue growth driven by VYVGART® adoption and a robust late-stage pipeline. Strong commercial execution and diversification make it a top growth pick in immunology.

BioMarin Pharmaceutical (BMRN)

Current Price (28 October 2025): $52.67

BioMarin focuses on rare genetic disorders and enzyme replacement therapies. Its new gene therapy Roctavian® for hemophilia A marks a major commercial milestone.

Key Details:

• Market Cap: $9.6 billion

• Revenue (TTM): $3.06 billion

• YoY Growth: 18.4%

Investor Appeal:

BioMarin’s strong rare-disease portfolio and the launch of Roctavian® support long-term growth potential and steady cash-flow generation in a niche, high-margin market.

Incyte Corporation (INCY)

Current Price (28 October 2025): $93.08

Incyte is an oncology and immunology company best known for Jakafi® and its expanding dermatology portfolio led by Opzelura®.

Key Details:

• Market Cap: $21.7 billion

• P/E ratio: 14.6

• Revenue (TTM): $4.58 billion

• YoY Growth: 18.9%

Investor Appeal:

Incyte combines reliable revenue from Jakafi® with solid growth from new indications and pipeline assets, appealing to investors seeking balance between stability and expansion.

CRISPR Therapeutics (CRSP)

Current Price (28 October 2025): $65.72

CRISPR Therapeutics pioneers gene-editing technologies and co-developed Casgevy®, the first FDA-approved CRISPR therapy for sickle-cell disease and β-thalassemia.

Key Details:

• Market Cap: $4.2 billion

• Revenue (TTM): $37.7 million

• YoY Growth: -86%

Investor Appeal:

As a leader in gene editing, CRISPR offers high-risk, high-reward exposure. Regulatory validation of Casgevy® confirms platform credibility, positioning the company for long-term potential despite short-term volatility.

Beam Therapeutics (BEAM)

Current Price (28 October 2025): $26.73

Beam Therapeutics develops next-generation gene-editing therapies using precision base editing technology designed to correct genetic mutations without cutting DNA. The company’s collaborations with Pfizer and Verve Therapeutics enhance its clinical reach.

Key Details:

• Market Cap: $2.2 billion

• Revenue (TTM): $60.3 million

• YoY Growth: -5%

Investor Appeal:

Beam represents a leading innovator in the gene-editing space. While early-stage and high-risk, its differentiated base-editing approach offers long-term potential as clinical programs mature.

Intellia Therapeutics (NTLA)

Current Price (28 October 2025): $14.79

Intellia Therapeutics focuses on in-vivo and ex-vivo CRISPR-based gene editing. It is among the first to demonstrate systemic in-vivo editing in humans with encouraging early clinical data in transthyretin amyloidosis.

Key Details:

• Market Cap: $1.3 billion

• Revenue (TTM): $52.9 million

• YoY Growth: +15%

Investor Appeal:

Intellia provides exposure to early-stage, high-impact genome-editing technologies. The company’s strong scientific partnerships and proof-of-concept studies support its long-term potential despite near-term losses.

Moderna (MRNA)

Current Price (28 October 2025): $26.66

Moderna is a global biotechnology leader pioneering mRNA-based vaccines and therapeutics. Following its COVID-19 success, the company is expanding into oncology, RSV, and rare-disease applications.

Key Details:

• Market Cap: $10.5 billion

• Revenue (TTM): $3.08 billion

• YoY Growth: -39%

Investor Appeal:

Moderna remains well-funded and continues to diversify its mRNA platform. Despite current revenue declines, its extensive pipeline and platform scalability offer solid long-term upside for patient investors.

Genmab A/S (GMAB.CO)

Current Price (28 October 2025): $214.58

Genmab operates as a Danish biotech organization which focuses on developing antibody-based cancer therapies through innovative approaches.

The DuoBody and HexaBody platforms developed by Genmab allow the creation of advanced immuno-oncology drugs which improve both safety and effectiveness thus establishing the company as a leading force in cancer treatment development.

Key Details:

• Market Cap: ~$85.6 billion

• Revenue (TTM): ~$19.02 billion

• YoY Growth: 25.43%

Investor Appeal:

Genmab generates consistent cash flow through its high-margin royalties which supports the development of its extensive oncology pipeline.

The company's proprietary platforms together with its strong partnerships with Janssen, AbbVie and BioNTech reduce risk and support growth, making it a financially strong biotech play.

CSL Limited (CSL.AX)

Current Price (28 October 2025): $139.93

CSL operates as a major Australian biopharmaceutical organization which focuses on plasma therapies alongside vaccines and rare disease treatments.

The company operates CSL Behring and Seqirus to deliver services across 60 nations while spending $1.5 billion yearly on research and development to drive innovation.

Key Details:

• Market Cap: ~$85.1 billion

• P/E ratio: 28.93

• Revenue (TTM): ~$14.8 billion

• YoY Growth: ~10.10%

Investor Appeal:

The company generates recession-proof revenue through its plasma operations while its various rare disease pipeline projects demonstrate strong growth potential.

The company's solid cash flow enables ongoing innovation and strategic expansion which makes it a reliable and growth-focused biotech investment.

Novo Nordisk (NVO)

Current Price (28 October 2025): $52.89

The company Novo Nordisk is a global leader in diabetes and obesity care, driven by its semaglutide-based therapies (like Wegovy® and Ozempic®). It continues to expand manufacturing capacity and global reach.

Key Details:

• Market Cap: ~$235.8 billion USD

• Revenue (TTM): ~$46.07 billion USD

• YoY Growth: ~21.5% (for the 12-months ending June 2025)

Investor Appeal:

Novo Nordisk offers exposure to fast-growing obesity/diabetes markets through a global franchise, backed by scale and innovation. While competitive and regulatory pressures exist, its breadth and leadership position make it a strong long-term candidate in the therapeutic growth space.

Lonza Group (LZAGY)

Current Price (28 October 2025): ~$70.25 USD (ADR)

Lonza Group operates as a major contract development and manufacturing organization (CDMO) in biologics, cell & gene therapies, and small molecules, servicing global pharma & biotech clients.

Key Details:

• Market Cap: ~$47.74 billion USD

• P/E ratio (trailing): ~52.3x

• Revenue (TTM): ~$7.09 billion USD (~CHF 7.09 b)

• YoY Growth: +5.9% approx for TTM ending June 2025

Investor Appeal:

Lonza is a play on pharma and biotech manufacturing secular growth (outsourcing, cell/gene therapy scale-up). For investors looking for more infrastructure/industrial biotech exposure with somewhat lower clinical risk, this offers a complementary angle.

Karuna Therapeutics (KRTX)

Current Price (as last listed): ~$329.83 USD (note: trading status may be uncertain)

Karuna is a clinical-stage biopharmaceutical company developing therapies for psychiatric and neurologic disorders (notably its lead candidate KarXT).

Key Details:

• Market Cap (as of last active data): ~$12.6 billion USD

• Revenue (TTM): Not meaningfully reported in public data (company is clinical-stage)

Investor Appeal:

Karuna presents a high-risk/high-reward opportunity in neuroscience, an area with historically limited innovation but large unmet need. For investors comfortable with clinical and regulatory risk, Karuna’s lead program could deliver significant upside if successful.

Madrigal Pharmaceuticals (MDGL)

Current Price (28 October 2025): $435.78

Madrigal develops therapies for liver-metabolic diseases (notably NASH/MAFLD) and has recently launched its first commercial product following FDA approval, positioning it for rapid growth.

Key Details:

• Market Cap: ~$9.7 billion

• Revenue (TTM): ~$515.6 million

• YoY Growth: ~3,400% (reflecting the transition from very low base)

Investor Appeal:

Madrigal is transitioning from early-stage into commercial execution. With its newly approved product in a large unmet-needs market and strong revenue growth, it offers high-growth potential, albeit with higher risk as commercial ramp-up and competition matter.

Viking Therapeutics (VKTX)

Current Price (28 October 2025): $35.93

Viking is a clinical-stage biotech developing metabolic and endocrine drugs, including oral candidates in obesity and liver disease.

Key Details:

• Market Cap: ~$3.8 billion

• Revenue (TTM): Not meaningfully reported 

Investor Appeal:

This is a higher-risk, higher-reward profile: limited current revenue but promising pipeline in large markets (obesity, metabolic disease). Investors comfortable with clinical/regulatory risk may view Viking as a speculative growth play.

Summit Therapeutics Inc. (SMMT)

Current Price (28 October 2025): $26.98

Summit Therapeutics operates as a U.S.based biopharmaceutical company which specializes in precision oncology through its lead asset Ivonescimab that targets TP53-mutant and other challenging-to-treat cancers.  The company has a key partnership with China-based Akeso Biopharma to co-develop and commercialize Ivonescimab globally.

Key Details:

• Market Cap: $20.5 billion

Investor Appeal:

The clinical emphasis of Summit on high-unmet-need cancers together with its late-stage pipeline and global partnerships makes it a potential breakout mid-cap in the oncology space. The continued success of Ivonescimab has the potential to transform treatment approaches for various tumor types.

Structure Therapeutics (GPCR)

Current Price (28 October 2025): ~$26.39

Structure Therapeutics is a clinical-stage biotech developing novel oral small-molecule therapies targeting G-protein coupled receptors (GPCRs) for metabolic and pulmonary diseases. Its lead candidate, GSBR-1290 (an oral GLP-1 R agonist), is in phase 2 trials for obesity and overweight conditions.

Key Details:

• Market Cap: ~$1.5 billion

• YoY Growth: Not meaningful (early stage)

Investor Appeal:

Structure Therapeutics offers a high-risk, high-reward profile: it’s targeting a large market (oral obesity/metabolic drugs) and has shown early efficacy (e.g., ~6.2 % weight loss in mid-stage trial of its oral GLP-1 candidate) which signals potential for meaningful upside.

However, as a clinical-stage company with no revenue, success depends heavily on trial outcomes, regulatory approval and eventual commercialization.

Key Catalysts & FDA Calendar for 2025

The year 2025 is shaping up to be a pivotal one for the biotech industry, with multiple high-impact regulatory decisions and clinical readouts expected.

Major catalysts include anticipated FDA approvals for next-generation therapies in obesity (Novo Nordisk, Structure Therapeutics), gene editing (CRISPR Therapeutics, Intellia), and autoimmune diseases (Argenx). Late-stage data from Madrigal Pharmaceuticals and Viking Therapeutics in liver-metabolic indications will also be closely watched.

Investors should track upcoming Advisory Committee meetings, Phase 3 trial results, and PDUFA dates, as these events often drive sharp short-term stock movements.

Building positions ahead of expected catalysts, while managing exposure, can create strong asymmetric opportunities across high-quality biotech names in 2025.

Building Your Biotech Portfolio: Risk-Managed Approach

Biotech investing requires balancing innovation potential with disciplined risk management. A well-constructed portfolio typically includes a mix of:

• Large-cap biopharma leaders (e.g., Novo Nordisk, Regeneron, Vertex) offering stable revenue and pipeline depth.

• Mid-cap innovators (e.g., Argenx, BioMarin, Alnylam) providing strong growth with moderate volatility.

• Emerging or clinical-stage developers (e.g., CRISPR, Beam, Viking) offering higher upside but greater risk.

Diversification across therapeutic areas, such as oncology, metabolic, gene therapy, and immunology, reduces idiosyncratic exposure.

Investors should size positions according to each company’s stage, regulatory risk, and funding strength, maintaining a core allocation to profitable firms while using smaller speculative bets for breakthrough potential.

Red Flags: When to Avoid Biotech Stocks

Despite exciting innovation, not all biotech companies make sound investments. Key warning signs include:

• Weak financials: insufficient cash runway (less than 12 months of liquidity) or heavy dilution from constant equity raises.

• Unproven leadership: lack of commercial execution experience or unclear strategic direction.

• Regulatory setbacks: repeated trial delays, failed endpoints, or withdrawn filings.

• Hype without data: excessive valuation driven by market sentiment rather than clinical validation.

Investors should also avoid chasing speculative rallies ahead of binary trial results without risk mitigation. A disciplined focus on data quality, balance-sheet strength, and pipeline visibility helps protect capital in the volatile biotech landscape.

Conclusion: Balancing Innovation & Caution

The 21 biotech stocks for 2025 represent both established leaders and high-growth innovators, which makes them exciting investment opportunities. The high potential rewards come with significant risks, which require investors to diversify their portfolios and conduct continuous research.

These biotech stock investment choices offer healthcare investors a solid foundation to access future healthcare opportunities. If you are looking to expand further, feel free to also explore areas like Pharma stocks and Healthcare stocks to build a well-rounded portfolio.